%0 Journal Article %A Dalkhat M. Ediev %T Population heterogeneity is a critical factor of the kinetics of the COVID-19 epidemics %D 2020 %R 10.1101/2020.06.25.20140442 %J medRxiv %P 2020.06.25.20140442 %X The novel coronavirus pandemic generates extensive attention in political and scholarly domains 1–4. Its potentially lasting prospects, economic and social consequences call for a better understanding of its nature. The widespread expectations of large portions of the population to be infected or vaccinated before containing the COVID-19 epidemics rely on assuming a homogeneous population. In reality, people differ in the propensity to catch the infection and spread it further. Here, we incorporate population heterogeneity into the Kermack-McKendrick SIR compartmental model 5 and show the cost of the pandemic may be much lower than usually assumed. We also indicate the crucial role of correctly planning lockdown interventions. We found that an efficient lockdown strategy may reduce the cost of the epidemic to as low as several percents in a heterogeneous population. That level is comparable to prevalences found in serological surveys 6. We expect that our study will be followed by more extensive data-driven research on epidemiological dynamics in heterogeneous populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been based on no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results presented are based on modeling and simulations. The relevant R code is provided in the Materials and Methods. %U https://www.medrxiv.org/content/medrxiv/early/2020/06/26/2020.06.25.20140442.full.pdf